A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2019
At a glance
- Drugs Belimumab (Primary) ; Rituximab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BLISS-BELIEVE
- Sponsors GlaxoSmithKline
- 21 Dec 2018 Planned number of patients changed from 200 to 280.
- 31 Aug 2018 Biomarkers information updated
- 10 Apr 2018 Planned End Date changed from 2 Jun 2021 to 9 Jun 2021.